Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 402 publications
Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens.
Journal: Expert review of hematology
Published: August 19, 2026
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026
Molecular subtypes and genetic diagnostics in B-cell acute lymphoblastic leukemia.
Journal: Human pathology
Published: July 13, 2026
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026
Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring.
Journal: Leukemia & lymphoma
Published: June 01, 2026
Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 27, 2026
Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 08, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.
Journal: Haematologica
Published: April 22, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.
Journal: Journal of hematology & oncology
Published: April 17, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Journal: Blood cancer journal
Published: April 12, 2026
SOHO State of the Art Updates and Next Questions | Management of High-Risk Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 10, 2026
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.
Journal: Leukemia
Published: March 31, 2026
Last Updated: 09/26/2026